866-997-4948(US-Canada Toll Free)

Aleglitazar (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 41 Pages


GlobalDatas pharmaceuticals report, Aleglitazar (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Aleglitazar sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Aleglitazar.
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Aleglitazar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2017-2020 for Aleglitazar in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Diabetes 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 6
2.3 Etiology and Risk Factors 8
2.3.1 Obesity 8
2.3.2 Sedentary Lifestyle 8
2.3.3 Family History and Genetics 8
2.3.4 Ethnicity 8
2.3.5 Old Age 8
2.4 Economic Impact of Diabetes 8
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type 1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Aleglitazar 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.4 Factors Affecting Sales 26
7.4.1 Improved Cardiovascular Outcome 26
7.4.2 Safety 26
7.4.3 Peroxisome Proliferator Activated Receptor (PPAR) Agonists 26
7.4.4 New Treatment Options 26
7.5 Drug Evaluation 27
7.5.1 Drug Risk Benefit Score 27
7.5.2 Intensity of Competition 28
7.6 Sales Forecasts 28
7.6.1 Target Patient Pool for Aleglitazar 28
7.6.2 Dosing 28
7.6.3 Market Penetration 28
7.6.4 Annual Cost of Therapy 29
7.6.5 Sales Projections of Aleglitazar 29

8 Diabetes Market: Appendix 37
8.1 Market Definitions 37
8.2 List of Abberiviations 37
8.3 Research Methodology 38
8.3.1 Coverage 38
8.3.2 Secondary Research 38
8.3.3 Forecasting 38
8.3.4 Net Penetration of Drug 39
8.3.5 Net Annual Dosing 39
8.3.6 Annual Cost of Therapy 39
8.3.7 Primary Research 39
8.3.8 Expert Panels 40
8.4 Drug Sales Estimates Model 40
8.5 Contact Us 40
8.6 Disclaimer 40
8.7 Sources 41

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales, 2010 
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 
Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 
Table 8: Diabetes Drugs Evolution 
Table 9: Phase II, ‘SYNCHRONY’ Clinical Study 
Table 10: Drug Risk Benefit Score of Aleglitazar 
Table 11: Aleglitazar, Type 2 Diabetes, Global, Sales Estimates ($m), 2017–2020 
Table 12: Aleglitazar, Type 2 Diabetes, the US, Sales Estimates ($m), 2017–2020 
Table 13: Aleglitazar, Type 2 Diabetes, the UK, Sales Forecasts ($m), 2017–2020 
Table 14: Aleglitazar, Type 2 Diabetes, France, Sales Forecasts ($m), 2011–2020 
Table 15: Aleglitazar, Type 2 Diabetes, Germany, Sales Estimates ($m), 2017–2010 
Table 16: Aleglitazar, Type 2 Diabetes, Italy, Sales Estimates ($m), 2017–2020 
Table 17: Aleglitazar, Type 2 Diabetes, Spain, Sales Estimates ($m), 2017–2010 

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 5
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 5
Figure 3: Diabetes, World, Mortality, 2010 6
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 7
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 12
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Aleglitazar, Type 2 Diabetes, Global, Sales Estimates ($m), 2017-2020 29
Figure 13: Aleglitazar, Type 2 Diabetes, the US, Sales Estimates ($m), 20172020 30
Figure 14: Aleglitazar, Type 2 Diabetes, the UK, Sales Estimates ($m), 20172020 31
Figure 15: Aleglitazar, Type 2 Diabetes, France, Sales Estimates ($m), 20172020 32
Figure 16: Aleglitazar, Type 2 Diabetes, Germany, Sales Estimates ($m), 20172020 33
Figure 17: Aleglitazar, Type 2 Diabetes, Italy, Sales Estimates ($m), 20172020 34
Figure 18: Aleglitazar, Type 2 Diabetes, Spain, Sales Estimates ($m), 20172020 35
Figure 19: Aleglitazar, Type 2 Diabetes, Global, Sales Distribution, 2020 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *